After Brexit the MHRA had been preparing to take over the role of sole approver of newly licensed medicines in the UK until now.
This exciting announcement details the new regulatory routes the MHRA will now recognise, giving UK patients faster access to new, cutting edge medicines.
Medicines which have been approved in Australia, Canada, the European Union, Japan, Switzerland, Singapore and the United States will be recognized by the MHRA as having undergone a sufficiently robust regulatory approval process, thus reducing the time required to make these medicines available on the UK market.
For more information see the MHRA’s original post at the address below:
